Your session is about to expire
← Back to Search
Behavioral Activation Therapy for Adolescent Depression
N/A
Waitlist Available
Led By Wade E Craighead, PhD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Is your child right-handed and between the ages of 15 and 17?
For payment purposes, does your child have a social security or tax identification number?
Must not have
Is there any reason your child would NOT be able to undergo multiple MRI scans?
Is your child currently receiving psychotherapy and/or medication for any psychological disorder?
Timeline
Screening 2 weeks
Treatment 16 weeks
Follow Up 1 weeks
Awards & highlights
Summary
This trial will compare brain activation of depressed adolescents before, during, and after a course of Behavioral Activation therapy, using functional magnetic resonance imaging. The goal is to see if BA therapy affects different neural mechanisms for behavioral avoidance associated with low motivation, as compared to threat avoidance.
Who is the study for?
Adolescents aged 15-17 with major depressive disorder (MDD) can join this trial. They must have a certain level of depression severity, an IQ over 80, and agree not to take other psychosocial treatments or psychotropic drugs before the study. Healthy controls without MDD are also needed. Exclusions include drug/alcohol abuse, serious medical conditions that overshadow MDD, claustrophobia, pregnancy, and inability to complete assessments. Full inclusion and exclusion criteria can be found at clinicaltrials.gov.Check my eligibility
What is being tested?
The trial is testing how Behavioral Activation Therapy affects brain activity in depressed teens using fMRI scans before, during and after therapy sessions. It aims to see if the therapy impacts areas of the brain related to motivation differently than those linked with threat avoidance.See study design
What are the potential side effects?
Behavioral Activation Therapy doesn't involve medication so typical drug side effects aren't expected; however participants may experience discomfort from being in an MRI machine such as claustrophobia or anxiety.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Timeline
Screening ~ 2 weeks0 visits
Treatment ~ 16 weeks5 visits
Follow Up ~ 1 weeks0 visits
Screening ~ 2 weeks
Treatment ~ 16 weeks
Follow Up ~1 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Adolescent Longitudinal Interval Follow-Up Evaluation (A-LIFE)
Change in Diagnostic Interview Status (CDRS-R) total score from baseline
Secondary outcome measures
Change in Beck Depression Inventory (BDI-II)
Trial Design
1Treatment groups
Experimental Treatment
Group I: MDD PatientsExperimental Treatment0 Interventions
Participants will be seen for a maximum of 16 sessions over 16 weeks. Two extra sessions will be allowed during treatment.
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,655 Previous Clinical Trials
2,572,347 Total Patients Enrolled
59 Trials studying Depression
8,818 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,820 Previous Clinical Trials
2,692,683 Total Patients Enrolled
675 Trials studying Depression
256,753 Patients Enrolled for Depression
Wade E Craighead, PhDPrincipal InvestigatorEmory University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: MDD Patients
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 2 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 16 Weeks
- Follow Ups: You may be asked to continue sharing information regarding the trial for 1 Weeks after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger